Basic Information
| LncRNA/CircRNA Name | NNT-AS1 |
| Synonyms | nicotinamide nucleotide transhydrogenase-antisense RNA1 |
| Region | GRCh38_5:43571594-43603230 |
| Ensemble | ENSG00000248092 |
| Refseq | NR_073113 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qRT-PCR, Western blot assay, Dual luciferase reporter assay |
| Sample | NSCLC samples,NSCLC cell lines H1650, A549 and H1299, and human lung epithelial cells BEAS-2B |
| Expression Pattern | up-regulated |
| Function Description | the levels of NNT-AS1 and YAP1 were enhanced, while miR-22-3p expression was decreased in NSCLC tissues and cells. High NNT-AS1 expression was correlated with poor prognosis. NNT-AS1 knockdown impeded proliferation, migration, invasion and EMT of NSCLC cells. NNT-AS1 targeted miR-22-3p, and YAP1 was a target of miR-22-3p in NSCLC cells. Furthermore, NNT-AS1 facilitated the progression of NSCLC by regulating miR-22-3p/YAP1 axis. NNT-AS1 knockdown repressed tumor growth in vivo. |
| Pubmed ID | 31923353 |
| Year | 2020 |
| Title | LncRNA NNT-AS1 Promotes Non-Small Cell Lung Cancer Progression Through Regulating miR-22-3p/YAP1 Axis |
External Links
| Links for NNT-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |